Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitroand in vivo

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Wei, Jiang ^a   Freytag, Marcus ^a   Schober, Yvonne ^b   Nockher, Wolfgang A ^b   Mautner, Victor F ^a   Friedrich, Reinhard E ^a   Manley, Paul W ^c   Kluwe, Lan ^a   Kurtz, Andreas ^d,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROFIBROMA; NONHUMAN; SCIATIC NERVE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR XENOGRAFT; WEIGHT GAIN; ANIMAL; BODY WEIGHT; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHILD; DRUG EFFECTS; DRUG SCREENING; NEUROFIBROMA, PLEXIFORM; NUDE MOUSE; PATHOLOGY; SCHWANN CELL; TUMOR CELL LINE;

ANIMALS; BENZAMIDES; BODY WEIGHT; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHILD; FEMALE; HUMANS; MICE, NUDE; NEUROFIBROMA, PLEXIFORM; PIPERAZINES; PYRIMIDINES; SCHWANN CELLS; SCIATIC NERVE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908583825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107760     Document Type: Article

References (23)

1. Cunha KS, Barboza EP, Fonseca EC (2008) Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics 63: 39-42.
2. Oates EC, Payne JM, Foster SL, Clarke NF, North KN (2013) Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge. Am J Med Genet A 161A: 659-666.
3. Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M (2011) Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics 5: 623-690.
4. Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, et al. (2011) Cancer stem celllike cells derived from malignant peripheral nerve sheath tumors. PLoS One 6: e21099.
5. Borrego-Diaz E, Terai K, Lialyte K, Wise AL, Esfandyari T, et al. (2012) Overactivation of Ras signaling pathway in CD133+ MPNST cells. J Neurooncol 108: 423-434.
6. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, et al. (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311-314.
7. Ward BA, Gutmann DH (2005) Neurofibromatosis 1: from lab bench to clinic. Pediatr Neurol 32:221-228.
8. Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, et al. (2012) Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 7(4):e35711.
9. Kitamura M, Wada N, Nagata S, Iizuka N, Jin YF, et al. (2010) Malignant peripheral nerve sheath tumor associated with neurofibromatosis type 1, with metastasis to the heart: a case report. Diagn Pathol 5: 2.
10. Brems H, Beert E, de Ravel T, Legius E (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10: 508-515.
11. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259.
12. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, et al. (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87: 197-203.
13. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, et al. (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445-453.
14. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, et al. (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26: 2197-2203.
15. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551.
16. Jiang W, Schnabel C, Spyra M, Mautner VF, Friedrich RE, et al. (2014) Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro. J Neurooncol 116: 231-236.
17. Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, et al. (2010) Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 98: 11-19.
18. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, et al. (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278: 51-57.
19. Gleiss J, Demestre M, Spyra M, Eschenhagen T, Hagel C, et al. (2013) B-scan ultrasonographic monitoring of orthotopic xenografted plexiform neurofibroma in mice. In Vivo 27: 723-727.
20. Götze L, Hegele A, Metzelder SK, Renz H, Nockher WA (2012) Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta 413: 143-149.
21. Gambacorti-Passerini CB, Rossi F, Verga M, Ruchatz H, Gunby R, et al. (2002) Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol Dis 28: 361-372.
22. Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, et al. (2012) Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer 59: 840-845.
23. Borg C, Terme M, Taïeb J, Ménard C, Flament C, et al. (2004) Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388.